CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.51 4.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.44

Máximo

1.51

Métricas clave
By Trading Economics
Ingresos	2.3M -18M
Ventas	-1.9M -193K
Margen de beneficios	9,174.093
Empleados	116
EBITDA	1.5M -16M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+703.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	8 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.7M 626M
Apertura anterior	-3.35
Cierre anterior	1.51

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.6818 / 0.74 Soporte y Resistencia

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 may 2026, 23:58 UTC

Ganancias

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 may 2026, 22:57 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 may 2026, 23:52 UTC

Ganancias

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 may 2026, 23:28 UTC

Charlas de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 may 2026, 23:11 UTC

Ganancias

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 may 2026, 23:06 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 may 2026, 23:05 UTC

Ganancias

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 may 2026, 23:04 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 may 2026, 23:02 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 may 2026, 23:00 UTC

Charlas de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 may 2026, 22:42 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 may 2026, 22:33 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 may 2026, 22:32 UTC

Ganancias

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie: 68% of FY Income From International >MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 may 2026, 22:29 UTC

Ganancias

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 may 2026, 22:26 UTC

Ganancias

Macquarie to End Share Buyback Extended in November>MQG.AU

7 may 2026, 22:25 UTC

Ganancias

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

703.47% repunte

Estimación a 12 Meses

Media 11.57 USD 703.47%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.